Dowling & Yahnke’s Fortress Biotech FBIO Stock Holding History

Dowling & Yahnke’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$17K	Hold	1,333	–	–	﹤0.01%	372
2022 Q2	$17K	Hold	1,333	–	–	﹤0.01%	373
2022 Q1	$27K	Hold	1,333	–	–	﹤0.01%	372
2021 Q4	$50K	Hold	1,333	–	–	﹤0.01%	374
2021 Q3	$64K	Hold	1,333	–	–	﹤0.01%	368
2021 Q2	$71K	Hold	1,333	–	–	﹤0.01%	365
2021 Q1	$71K	Hold	1,333	–	–	﹤0.01%	334
2020 Q4	$63K	Hold	1,333	–	–	﹤0.01%	323
2020 Q3	$81K	Hold	1,333	–	–	0.01%	301
2020 Q2	$54K	Hold	1,333	–	–	﹤0.01%	295
2020 Q1	$38K	Hold	1,333	–	–	﹤0.01%	287
2019 Q4	$51K	Hold	1,333	–	–	﹤0.01%	320
2019 Q3	$28K	Hold	1,333	–	–	﹤0.01%	303
2019 Q2	$30K	Hold	1,333	–	–	﹤0.01%	293
2019 Q1	$36K	Buy	+1,333	New	+$35K	﹤0.01%	255

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dowling & Yahnke's FBIO Position: Q3 2022 in Review

Dowling & Yahnke held its Fortress Biotech (FBIO) position steady in Q3 2022 at 1,333 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #372.

Dowling & Yahnke first reported a position in FBIO in Q1 2019 and has held it in 15 quarters since. The position peaked at $81K in Q3 2020. 64 funds tracked by Wall St. Rank hold FBIO as of Q3 2022.

Dowling & Yahnke held 1,333 shares of Fortress Biotech worth $17K as of Q3 2022.
Dowling & Yahnke left its Fortress Biotech share count unchanged in Q3 2022.
Fortress Biotech made up ﹤0.01% of Dowling & Yahnke's portfolio in Q3 2022, its #372 holding.
Dowling & Yahnke first reported a position in Fortress Biotech in Q1 2019 and has held it in 15 quarters since.
Dowling & Yahnke's Fortress Biotech position peaked at $81K in Q3 2020.
64 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.